NASDAQ:ONS Oncobiologics (ONS) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free ONS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$8.14▼$8.5050-Day Range$0.72▼$7.4052-Week Range$0.57▼$1.53Volume120,913 shsAverage Volume69,024 shsMarket Capitalization$608.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Oncobiologics alerts: Email Address Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Oncobiologics Stock (NASDAQ:ONS)Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification, development, manufacture, and commercialization of ONS-5010/LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.Read More Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. ONS Stock News HeadlinesAugust 2, 2023 | mirror.co.ukBBC slammed for 'biased' Wimbledon coverage of Marketa Vondrousova vs Ons Jabeur finalJuly 30, 2023 | mirror.co.ukOns Jabeur ‘kicked off’ Wimbledon centre court moments before women’s finalApril 29, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. April 27, 2023 | nytimes.comAre Away Carry-Ons Worth the Hype?October 5, 2022 | dailymail.co.ukONS - the Office of National StatisticsSee More Headlines Receive ONS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncobiologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ONS Previous SymbolNYSE:ONS CUSIPN/A CIK1649989 Webwww.oncobiologics.com Phone(609) 619-3990FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,840,000.00 Net Margins-464.47% Pretax MarginN/A Return on EquityN/A Return on Assets-93.28% Debt Debt-to-Equity RatioN/A Current Ratio0.41 Quick Ratio0.41 Sales & Book Value Annual Sales$3.81 million Price / Sales159.75 Cash FlowN/A Price / Cash FlowN/A Book Value($1.36) per share Price / Book-6.20Miscellaneous Outstanding Shares72,200,000Free FloatN/AMarket Cap$608.65 million OptionableNot Optionable Beta-0.27 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesLawrence A. KenyonPresident, CEO, CFO, Secretary & TreasurerTerry DagnonChief Operating OfficerJennifer M. KissnerSenior Vice President-Clinical DevelopmentJeff EvansonChief Commercial OfficerKey CompetitorsProKidneyNASDAQ:PROKPrime MedicineNYSE:PRMEAllogene TherapeuticsNASDAQ:ALLONovavaxNASDAQ:NVAXValnevaNASDAQ:VALNView All Competitors ONS Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Oncobiologics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oncobiologics investors own include CRISPR Therapeutics (CRSP), Network-1 Technologies (NTIP), Allena Pharmaceuticals (ALNA), Intra-Cellular Therapies (ITCI), Cidara Therapeutics (CDTX), Neuralstem (CUR), Exelixis (EXEL), Fate Therapeutics (FATE), Ampliphi Biosciences (APHB) and Ardelyx (ARDX). When did Oncobiologics IPO? Oncobiologics (ONS) raised $35 million in an initial public offering on Friday, May 13th 2016. The company issued 5,800,000 shares at $6.00 per share. Jefferies and Barclays served as the underwriters for the IPO and Cantor Fitzgerald & Co. was co-manager. This page (NASDAQ:ONS) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryHas Jeff Bezos Found the Next Nvidia?InvestorPlaceThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncobiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
